Metraipolis › archive › dc_5ae231ac01f4

UK Real-World Evidence of Using Durvalumab Plus Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer via an Early Access Scheme — Europe PMC PMID:40940830

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40940830
DOI
10.3390/cancers17172732
License (as archived)
solo-consultazione
Archived
2026-11-10T10:33:49.472Z
SHA-256 of the archived text
d028a8268e0fca371c845d6d53a20ba93dabe7a536a78c8e9b6771edbf3f51fa
Stable URL of this page
https://metraipolis.com/documento/dc_5ae231ac01f4

How to cite

UK Real-World Evidence of Using Durvalumab Plus Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer via an Early Access Scheme — Europe PMC PMID:40940830 — Europe PMC (en), https://europepmc.org/article/MED/40940830 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_5ae231ac01f4 (Metraipolis archive dc_5ae231ac01f4, sha256 d028a8268e0fca371c845d6d53a20ba93dabe7a536a78c8e9b6771edbf3f51fa)
BibTeX
@misc{dc5ae231ac01f4,
  title = {UK Real-World Evidence of Using Durvalumab Plus Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer via an Early Access Scheme — Europe PMC PMID:40940830},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40940830},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_5ae231ac01f4; sha256 d028a8268e0fca371c845d6d53a20ba93dabe7a536a78c8e9b6771edbf3f51fa},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40940830. Agents can read the archived copy with the MCP tool read_document.